Cannabinoid CB1 receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo

Citation
E. Acquas et al., Cannabinoid CB1 receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo, EUR J PHARM, 401(2), 2000, pp. 179-185
Citations number
24
Categorie Soggetti
Pharmacology & Toxicology
Journal title
EUROPEAN JOURNAL OF PHARMACOLOGY
ISSN journal
00142999 → ACNP
Volume
401
Issue
2
Year of publication
2000
Pages
179 - 185
Database
ISI
SICI code
0014-2999(20000804)401:2<179:CCRAIR>2.0.ZU;2-V
Abstract
Intravenous administration of the cannabinoid CB, receptor agonists (R-(+)- [2,3-Dihydro-5-methyl-3[morpholinyl)me pyrrolo[1,2,3-de]-1,4-benzoxazinyl]- (1-naphthalenyl)methanone mesylate), WIN 55,212-2 (10, 37.5, 75 and 150 mu g/kg), and ((6aR)trans-3-(1, 1-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hyd roxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol), HU 210 (1 and 4 mu g/kg ) dose-dependently increased acetylcholine release in dialysates from the p refrontal cortex and the hippocampus of freely moving rats. Administration of the cannabinoid receptor antagonist {N-(piperidin-1-yl)-5-(4-chloropheny l)-1-(2,3-dichlorophenyl)-3-methyl-1H-pyrazole-3carboxamide}HCl, SR 141716A , at a dose that per se did not affect basal acetylcholine release (2.5 mu g/kg), prevented the increase of acetylcholine release by WIN 55,212-2 (150 mu g/kg i.v.) or by HU 210 (4 mu g/kg i.v.) in both areas. These data demo nstrate that, at low i.v. doses, the synthetic cannabinoid CB1 receptor ago nists, WIN 55,212-2 and HU 210 stimulate cortical and hippocampal acetylcho line release. (C) 2000 Elsevier Science B.V. All rights reserved.